| 20.75 -0.09 (-0.43%) | 09-19 12:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.47 | 1-year : | 32.08 |
| Resists | First : | 23.52 | Second : | 27.47 |
| Pivot price | 20.01  |
|||
| Supports | First : | 20.11 | Second : | 18 |
| MAs | MA(5) : | 19.7 |
MA(20) : | 20.31 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 49.5 |
D(3) : | 33.5 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 28.07 | Low : | 16.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RAPP ] has closed below upper band by 27.0%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 21.8 - 21.88 | 21.88 - 21.94 |
| Low: | 18.95 - 19.05 | 19.05 - 19.12 |
| Close: | 20.69 - 20.84 | 20.84 - 20.97 |
Thu, 04 Jul 2024
Rapport Therapeutics director James Healy buys $1.08 million in company stock - Investing.com Australia
Thu, 13 Jun 2024
Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement - Goodwin Procter
Tue, 11 Jun 2024
Rapport Therapeutics director buys $9.5 million in company stock By Investing.com - Investing.com Australia
Fri, 07 Jun 2024
Rapport Therapeutics raises up to $154 million in IPO - The Business Journals
Fri, 07 Jun 2024
J&J-backed Rapport Therapeutics prices IPO at $17 per share - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 37 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 103 (%) |
| Shares Short | 1,300 (K) |
| Shares Short P.Month | 1,030 (K) |
| EPS | -1.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -12.15 |
| PEG Ratio | 0 |
| Price to Book value | 2.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|